Management of Multivessel Intracranial Stenosis with Bilateral Putamen Infarcts
Initiate antiplatelet therapy immediately with aspirin 81-325 mg daily, aggressively manage atherosclerotic risk factors including high-intensity statin therapy, and perform comprehensive cardiac evaluation to identify the cause of syncope, as this patient has symptomatic intracranial atherosclerotic disease requiring urgent medical optimization. 1, 2, 3
Immediate Antiplatelet Therapy
Start aspirin 81-325 mg daily immediately as first-line antiplatelet therapy for symptomatic intracranial atherosclerotic disease involving multiple territories (ACA, PCA, MCA M2 branch). 1, 2, 3
Alternative antiplatelet options if aspirin is contraindicated include clopidogrel 75 mg daily or the combination of aspirin plus extended-release dipyridamole (25 and 200 mg twice daily). 1, 2
Dual antiplatelet therapy (aspirin plus clopidogrel) for 21-90 days may be considered given the high-risk presentation with multiple vessel involvement and recent symptomatic events, though this must be balanced against bleeding risk in this 76-year-old patient. 4
Aggressive Risk Factor Management
Initiate high-intensity statin therapy immediately to reduce atherosclerotic burden and prevent recurrent stroke, targeting aggressive LDL reduction. 5, 6, 7
Blood pressure optimization is critical—aim for systolic blood pressure 130-150 mmHg to prevent both recurrent ischemia and hemorrhagic transformation. 8, 6
Medical therapy should follow the same aggressive risk reduction strategies used for extracranial carotid disease, including diabetes management, smoking cessation, and lifestyle modification. 1, 2, 3, 2
Critical Syncope Evaluation
The syncopal episode requires urgent investigation as it may indicate:
Cardiac arrhythmia (given age and atherosclerotic burden)—obtain continuous cardiac monitoring, echocardiography, and consider Holter monitoring. 3, 2
Hemodynamic compromise from multivessel stenosis—assess for orthostatic hypotension and ensure adequate cerebral perfusion pressure. 3, 2
Vertebrobasilar insufficiency—the bilateral putamen infarcts and multivessel disease suggest possible posterior circulation involvement requiring dedicated vertebral artery imaging. 1, 2, 9, 3
Advanced Vascular Imaging
Perform catheter-based contrast angiography if revascularization is being considered, as neither MRA nor CTA reliably delineates the severity and exact location of intracranial stenoses, particularly at vessel origins. 2, 3, 2
Serial noninvasive imaging (CTA or MRA) is reasonable to assess progression of atherosclerotic disease and monitor for development of new lesions. 2, 9, 3, 2
Revascularization Considerations
Endovascular intervention is NOT routinely recommended for this patient at present because:
The evidence for intracranial angioplasty/stenting remains limited with periinterventional stroke rates of 7.9% and death rates of 3.4%. 10
The WASID trial demonstrated that aspirin and warfarin were equally efficacious for symptomatic intracranial disease, with warfarin showing higher adverse event rates. 10, 2
Medical management is the primary treatment for symptomatic intracranial atherosclerotic disease unless there is evidence of recurrent symptoms despite optimal medical therapy. 1, 2, 10, 3
Prostate Cancer Considerations
Review the patient's prostate cancer treatment history and current androgen deprivation therapy status, as these may influence cardiovascular risk and bleeding risk with antiplatelet therapy. 11, 12, 13
Coordinate with oncology regarding any planned procedures or systemic therapies that might affect stroke management decisions. 11, 12
Monitoring and Follow-up
Admit for stroke unit care with continuous neurological monitoring given the acute bilateral putamen infarcts and multivessel disease. 6, 7
Monitor for hemorrhagic transformation, particularly given the bilateral nature of infarcts and need for antiplatelet therapy. 8, 6
Serial imaging at 3-6 months to assess stenosis progression and guide ongoing management decisions. 2, 9, 3, 2
Key Pitfalls to Avoid
Do not anticoagulate with warfarin—the WASID trial showed no benefit over aspirin with significantly higher bleeding and adverse event rates in intracranial stenosis. 10, 2
Avoid premature endovascular intervention—medical management should be optimized first, as revascularization carries substantial procedural risks without proven superiority over medical therapy. 10
Do not overlook the syncope—this may represent a separate life-threatening cardiac etiology requiring immediate attention beyond the stroke management. 3, 2